Research location
Saint-Grégoire
France
Advertisement
Research activity in Saint-Grégoire
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 65 trials and 65 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Saint-Grégoire
65 linked trials · page 1 of 2Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · 2026-06-05 · 1 site observation
RECRUITING
Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive EpisodeNCT06601140 · 2025-03-05 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate CancerNCT05346848 · 2023-02-24 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19 · 1 site observation
RECRUITING
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyNCT06680596 · 2025-07-30 · 1 site observation
ENROLLING_BY_INVITATION
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibNCT05625087 · 2023-10-19 · 1 site observation
ACTIVE_NOT_RECRUITING
PRostate Olaparib Real World Evidence StudyNCT06031805 · 2023-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28 · 1 site observation
COMPLETED
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNCT05901649 · 2023-07-05 · 1 site observation
COMPLETED
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.NCT05683977 · 2022-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerNCT05296746 · 2022-05-03 · 1 site observation
ACTIVE_NOT_RECRUITING
5 and 7-year Follow-up of the YOMEGA Trial CohortNCT05549271 · 2022-04-01 · 1 site observation
UNKNOWN
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · 2022-02-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsNCT05103605 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · 2020-10-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over ChemotherapyNCT04533958 · 2020-09-28 · 1 site observation
COMPLETED
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive PatientsNCT04115007 · 2020-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsNCT03870919 · 2019-10-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast CarcinomaNCT03630913 · 2019-01-08 · 1 site observation
UNKNOWN
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic CancersNCT03323424 · 2019-01-01 · 1 site observation
WITHDRAWN
Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric BypassNCT03610256 · 2018-10-18 · 1 site observation
COMPLETED
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerNCT02799706 · 2017-09-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960 · 2017-09-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate CancerNCT03088124 · 2017-04-28 · 1 site observation
COMPLETED
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionNCT03079011 · 2017-03-22 · 1 site observation
COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation
COMPLETED
Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)NCT02704832 · 2016-09-30 · 1 site observation
COMPLETED
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.NCT02585388 · 2015-10-23 · 1 site observation
TERMINATED
Therapeutic Nipple Sparing Mastectomy.NCT02311959 · 2015-02-09 · 1 site observation
COMPLETED
Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate CancerNCT02876237 · 2015-02-01 · 1 site observation
COMPLETED
An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast CancerNCT02286362 · 2015-01-14 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837 · 2014-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerNCT02423603 · 2014-05-14 · 1 site observation
COMPLETED
Omega Loop Versus Roux-en-Y Gastric BypassNCT02139813 · 2014-05-01 · 1 site observation
COMPLETED
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerNCT02216786 · 2014-01-16 · 1 site observation
COMPLETED
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · 2013-11-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerNCT01997333 · 2013-11-01 · 1 site observation
COMPLETED
First Line Metastatic Breast Cancer Treatment (ESMERALDA)NCT01941407 · 2013-11-01 · 1 site observation
COMPLETED
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerNCT01946204 · 2013-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical CareNCT02236637 · 2013-06-14 · 1 site observation
COMPLETED
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 YearsNCT01810393 · 2013-06-11 · 1 site observation
COMPLETED
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerNCT01572038 · 2012-06-01 · 1 site observation
COMPLETED
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT01566721 · 2012-05-17 · 1 site observation
COMPLETED
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine TreatmentNCT01564056 · 2012-04-12 · 1 site observation
COMPLETED
A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast CancerNCT01548534 · 2012-02-01 · 1 site observation
TERMINATED
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456 · 2011-10-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.